Lung Cancer Clinical Trial
Official title:
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more
effective with or without celecoxib in treating non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed
disodium, and carboplatin to compare how well they work when given together with celecoxib or
a placebo in treating patients with advanced non-small cell lung cancer.
OBJECTIVES:
Primary
- To confirm the beneficial effect of gemcitabine hydrochloride or pemetrexed disodium in
combination with carboplatin with or without celecoxib in patients with advanced
non-small cell lung cancer that expresses COX-2.
Secondary
- To describe the response rate in patients treated with these regimens.
- To describe the distribution of progression-free survival (PFS) and overall survival of
patients treated with these regimens.
- To compare the PFS of patients with COX-2 index ≥ 2 (adjusting for CYP2C9 genotype and
celecoxib trough concentrations as covariates) treated with these regimens.
- To correlate urinary PGE-M level with COX-2 expression, COX-2 inhibition, and outcome.
- To evaluate the association between the -765G/C polymorphism in PTGS2 and COX-2
expression in non-small cell lung cancer specimens.
- To characterize a trough plasma celecoxib concentration which will be used as a measure
of patient adherence to study treatment and which may be used in future studies for
correlations with genotype and pharmacodynamic outcomes.
OUTLINE: This is a multicenter study. Patients are stratified according to gender, disease
stage (IIIB vs IV), histology (squamous cell carcinoma vs non-squamous cell carcinoma),
smoking status (never/former light smoker [defined as ≤ 10 pack years AND quit ≥ 1 year ago]
vs smoker), and COX-2 expression status (COX-2 index ≥ 4 vs COX-2 index ≥ 2 but < 4).
Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed
disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib
twice daily on days 1-21.
- Arm II: Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and
carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
- NOTE: *Patients with squamous cell carcinoma receive gemcitabine hydrochloride; patients
with non-squamous cell carcinoma receive pemetrexed disodium.
In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity. After completion of 6 courses, patients with responding
or stable disease may continue to receive celecoxib or placebo alone in the absence of
disease progression or unacceptable toxicity.
Patients may undergo blood and urine sample collection periodically for correlative
laboratory studies.
After completion of study therapy, patients are followed up every 2 months for 2 years and
then every 6 months for 3 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|